Literature DB >> 8345609

Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study.

C C Schulman1, A Corbusier, H Michiels, H J Taenzer.   

Abstract

We treated 166 patients suffering from recurrent urinary tract infections under double-blind conditions for 3 months with 1 capsule daily of either the immunostimulating bacterial extract (85) or a placebo (81), followed by a 3-month observation period without the test drugs. The bacterial extract exerted a significant beneficial curative action and long-term consolidative effect on the frequency of recurrent urinary tract infections with marked improvements in the characteristic signs and symptoms. It was significantly superior to placebo for the majority of the assessed parameters: number of recurrent urinary tract infections, bacteriuria, leukocyturia, erythrocyturia, nitrituria, albuminuria and casts in urine. Consumption of antibiotics, chemotherapeutics, urinary antiseptics or disinfectants was significantly less under active drug therapy compared to placebo. Tolerance was good with only 2 side effects reported in 2 patients (2%) in the active group compared to 11 among 5 (6%) in the placebo group. Therefore, the bacterial extract can be considered an efficient and well tolerated drug for the treatment of urinary tract infections, and their accompanying signs and symptoms, as well as for decreasing the risk of recurrences and the need for antibiotics and other antibacterial drugs.

Entities:  

Mesh:

Year:  1993        PMID: 8345609     DOI: 10.1016/s0022-5347(17)35648-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study.

Authors:  Davide De Vita; Salvatore Giordano
Journal:  Int Urogynecol J       Date:  2012-05-22       Impact factor: 2.894

Review 2.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

3.  Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis.

Authors:  Seung-Ju Lee; Sae Woong Kim; Yong-Hyun Cho; Moon Soo Yoon
Journal:  World J Urol       Date:  2005-12-31       Impact factor: 4.226

4.  A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections.

Authors:  Andrew Brodie; Omar El-Taji; Ibrahim Jour; Charlotte Foley; Damian Hanbury
Journal:  Curr Urol       Date:  2020-10-13

Review 5.  Urinary tract infections in adult general practice patients.

Authors:  Eva Hummers-Pradier; Michael M Kochen
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

6.  Evaluation of the effects of ozone therapy on Escherichia coli-induced cytitis in rat.

Authors:  C Tasdemir; S Tasdemir; N Vardi; B Ates; Y Onal; S Erdogan; A Yucel; E Aglamis; Y Yakupogullari; R Altıntas; A Karaman
Journal:  Ir J Med Sci       Date:  2013-03-01       Impact factor: 1.568

7.  A prospective multi-center trial of Escherichia coli extract for the prophylactic treatment of patients with chronically recurrent cystitis.

Authors:  Kun Suk Kim; Ji-Yoon Kim; In Gab Jeong; Jae-Seung Paick; Hwancheol Son; Dae Jung Lim; Hong Bang Shim; Won Hee Park; Hee Chang Jung; Myung-Soo Choo
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

8.  Recurrent Urinary Tract Infections Management in Women: A review.

Authors:  Ahmed Al-Badr; Ghadeer Al-Shaikh
Journal:  Sultan Qaboos Univ Med J       Date:  2013-06-25

9.  Effectiveness of intravesical hyaluronic acid with or without chondroitin sulfate for recurrent bacterial cystitis in adult women: a meta-analysis.

Authors:  Davide De Vita; Henrik Antell; Salvatore Giordano
Journal:  Int Urogynecol J       Date:  2012-11-06       Impact factor: 2.894

Review 10.  Waging war against uropathogenic Escherichia coli: winning back the urinary tract.

Authors:  Kelsey E Sivick; Harry L T Mobley
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.